AGI-1067: Phase IIb interim data

Interim data from 133 patients in the placebo-controlled Phase IIb CART-2 trial showed AGI-1067 significantly reduced coronary atherosclerosis from baseline,

Read the full 209 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE